ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many other rectal cancer trials and a spattering of neoadjuvant colorectal trials, the ability to redefine and provide clarity to this area is pertinent. Today, it heavily focuses on immunotherapy in the colon space with sintilimab and IBI310 battling it out with the old master pembrolizumab. The rectal contingent is the TNTCRT trial, looking at total neoadjuvant therapy vs concurrent chemoradiotherapy. While the world may have moved forward, this trial could provide further evidence of the path we should be taking.

Links to studies discussed in this episode (subscription may be required)

NEOPRISM-CRC: Link

TNTCRC: Link

Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labelled, phase Ib study: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.